For patients with advanced non–small cell lung cancer (aNSCLC) and obesity who potentially have an inadequate therapeutic response to anti–programmed cell death 1 therapy, is conventional chemotherapy or immune checkpoint inhibitor the optimal choice as first-line therapy? The gene discussed is PDCD1; the disease is obesity due to melanocortin 4 receptor deficiency.